The genetic constituent of varicose vein pathogenesis as a key for future treatment option development

Abstract

This perspective focuses primarily on the fundamental part of phlebology, where most attention is paid to the genetic aspects of the pathogenesis of varicose vein disease and where the main breakthrough advances in this area of research are discussed. We propose a direction for further actions to replenish molecular genetic knowledge about the main drivers of pathological processes in varicose vein disease and to complete the creation of an entire picture of pathogenesis, which, in turn, may serve as a key for the development of treatment options in the future in order to translate research evidence into clinical practice.

Keywords

Varicose veins / pathogenesis / genetics / epigenetics / targets

References

[1] Ottley C.Heredity and varicose veins.Br Med J1934;1:528 PMCID:PMC2444750

[2] Wagner FB.Etiology of primary varicose veins.Am J Surg1949;78:876-80

[3] Vanhoutte PM,de Montrion C.Venous disease: from pathophysiology to quality of life.Angiology1997;48:559-67

[4] Meissner MH,Bergan J.Primary chronic venous disorders.J Vasc Surg2007;46 Suppl S:54S-67S

[5] Hauge M.Genetics of varicose veins of the lower extremities.Hum Hered1969;19:573-80

[6] Matousek V.A contribution to the problem of the inheritance of primary varicose veins.Hum Hered1974;24:225-35

[7] Cornu-Thenard A,Baud JM,Carpentier PH.Importance of the familial factor in varicose disease. Clinical study of 134 families.J Dermatol Surg Oncol1994;20:318-26

[8] Guo Q.Genetic analysis of varicose vein of lower extremities. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 1998;15:221-3. (in Chinese)

[9] Serra R,de Franciscis A.A genetic study of chronic venous insufficiency.Ann Vasc Surg2012;26:636-42

[10] Pistorius MA.Chronic venous insufficiency: the genetic influence.Angiology2003;54 Suppl 1:S5-12

[11] Krysa J,van Rij AM.Evidence for a genetic role in varicose veins and chronic venous insufficiency.Phlebology2012;27:329-35

[12] Smetanina MA,Zolotukhin IA.The genetic base of chronic venous disease: a review of modern concepts.Flebol2016;10:199. (in Russian)

[13] Shadrina AS,Sevost'ianova KS.Polymorphic variants rs13155212 (T/C) and rs7704267 (G/C) in the AGGF1 gene and risk of varicose veins of the lower extremities in the population of ethnic Russians.Bull Exp Biol Med2016;161:698-702

[14] Shadrina AS,Shevela AI.Polymorphisms in the MTHFR and MTR genes and the risk of varicose veins in ethnical Russians.Biomarkers2016;21:619-24

[15] Shadrina AS,Sevost'yanova KS.Polymorphism of matrix metalloproteinases genes MMP1, MMP2, MMP3, and MMP7 and the risk of varicose veins of lower extremities.Bull Exp Biol Med2017;163:650-4

[16] Sokolova EA,Sevost'ianova KS.HFE p.C282Y gene variant is associated with varicose veins in Russian population.Clin Exp Med2016;16:463-70

[17] Shadrina AS,Sokolova EA.Association of polymorphisms near the FOXC2 gene with the risk of varicose veins in ethnic Russians.Phlebology2016;31:640-8

[18] Shadrina AS,Sokolova EA.Allele rs2010963 C of the VEGFA gene is associated with the decreased risk of primary varicose veins in ethnic Russians.Phlebology2018;33:27-35

[19] Shadrina AS,Sevost'ianova KS.Functional polymorphism rs1024611 in the MCP1 gene is associated with the risk of varicose veins of lower extremities.J Vasc Surg Venous Lymphat Disord2017;5:561-6

[20] Shadrina A,Smetanina M.Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians.Immunol Res2018;66:141-50

[21] Bell RK,McLean CY,Tung JY. A large scale genome wide association study of varicose veins in the 23andMe cohort. In: The 64th Annual Meeting of The American Society of Human Genetics; 2014 Oct 18-22; San Diego, USA: ASHG. Paper no. 2082M; p. 487.

[22] Ellinghaus E,Krusche P.Genome-wide association analysis for chronic venous disease identifies EFEMP1 and KCNH8 as susceptibility loci.Sci Rep2017;7:45652 PMCID:PMC5379489

[23] Shevela AI,Plotnikova EY,Filipenko ML.Altered expression of the extracellular matrix related genes COL15A1, CHRDL2, EFEMP1, and TIMP1 in Varicose Veins.Eur J Vasc Endovasc Surg2020;60:e75-6

[24] Shadrina A,Sokolova E.Genome-wide association study in ethnic Russians suggests an association of the MHC class III genomic region with the risk of primary varicose veins.Gene2018;659:93-9

[25] Shadrina A,Smetanina M.Polymorphisms of genes involved in inflammation and blood vessel development influence the risk of varicose veins.Clin Genet2018;94:191-9

[26] Fukaya E,Lindholm D.Clinical and genetic determinants of varicose veins.Circulation2018;138:2869-80 PMCID:PMC6400474

[27] Shadrina AS,Shashkova TI.Varicose veins of lower extremities: Insights from the first large-scale genetic study.PLoS Genet2019;15:e1008110 PMCID:PMC6490943

[28] Smetanina MA,Zolotukhin IA,Filipenko ML.Differentially expressed genes in varicose veins disease: current state of the problem, analysis of the Published Data.Flebol2017;11:190. (in Russian)

[29] Smetanina M,Seliverstov E,Filipenko M.Differentially Expressed genes in lower limb varicose vein disease.Flebol2020;14:122. (in Russian)

[30] Smetanina MA,Sevost'ianova KS.DNA methylation and gene expression profiling reveal MFAP5 as a regulatory driver of extracellular matrix remodeling in varicose vein disease.Epigenomics2018;10:1103-19

[31] Smetanina MA,Sevostyanova KS,Zolotukhin IA. Two CpG loci in the regulatory regions of the MFAP5 gene are hypomethylated in varicose veins. In: ABSTRACTS of the International Union of Phlebology Chapter Meeting; 2019 Aug 25-27; Krakow, Poland. Phlebological Review 2019;1:23-4.

[32] Smetanina MA,Gavrilov KA. Modified methylation of the DNA loci related to the genes HRC, DPEP2, and CCN5 in varicose veins. In: BOOK OF ABSTRACTS of the 13th St. Petersburg Venous Forum (Christmas Meetings); 2020 Dec 4-5; St. Petersburg, Russia. ADVANCED PROBLEMS IN PHLEBOLOGY; 2020. p. 11-12.

[33] Lim JP.Bridging the transgenerational gap with epigenetic memory.Trends Genet2013;29:176-86 PMCID:PMC3595609

[34] Legoff L,Tevosian S,Smagulova F.Transgenerational Inheritance of Environmentally Induced Epigenetic Alterations during Mammalian Development.Cells2019;8:1559 PMCID:PMC6953051

[35] Bradbury J.Human epigenome project--up and running.PLoS Biol2003;1:E82 PMCID:PMC300691

[36] Ashar FN,Longchamps RJ.Association of mitochondrial DNA copy number with cardiovascular disease.JAMA Cardiol2017;2:1247-55 PMCID:PMC5710361

[37] Smetanina MA,Shirshova AN. Quantitative and structural characteristics of mitochondrial DNA in varicose veins. In: SCIENTIFIC PROGRAMME AND BOOK OF ABSTRACTS of the 20th Annual Meeting of the European Venous Forum; 2019 June 27-29; Zurich, Switzerland. Edizioni Minerva Medica;24.

[38] Castellani CA,Sumpter JA.Mitochondrial DNA copy number can influence mortality and cardiovascular disease via methylation of nuclear DNA CpGs.Genome Med2020;12:84 PMCID:PMC7523322

[39] Kharkevich DA.Venotropic (phlebotropic) agents. Eksp Klin Farmakol 2004;67:69-77. (in Russian) [PMID: 15079914]

[40] Felixsson E,Eriksson AC.Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study.Phytother Res2010;24:1297-301

[41] Feldo M,Sowa I.Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.Molecules2019;24:3316 PMCID:PMC6767141

[42] Ivanov V,Kalinovsky T,Rath M.Bioflavonoids effectively inhibit smooth muscle cell-mediated contraction of collagen matrix induced by angiotensin II.J Cardiovasc Pharmacol2005;46:570-6

[43] Zheng Y,Shi W.Metabolism and pharmacological activities of the natural health-benefiting compound diosmin.Food Funct2020;11:8472-92

[44] Coccheri S.Development and use of sulodexide in vascular diseases: implications for treatment.Drug Des Devel Ther2013;8:49-65 PMCID:PMC3879015

[45] Zolotukhin IA,Smetanina MA,Filipenko ML.Varicose veins: on the verge of discovering the cause?.Annals RAMS2020;75:36-45. (in Russian)

[46] Maggioli A.Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction.Phlebolymphology2016;23:82-91

[47] Ramelet AA.Venoactive Drugs. In: Goldman MP, Weiss RA, editors. Sclerotherapy 6th ed. Treatment of Varicose and Telangiectatic Leg Veins. Elsevier; 2017. pp. 426-34.

[48] Mansilha A.Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy.Int J Mol Sci2018;19:1669 PMCID:PMC6032391

[49] Paysant J,Bouskela E.Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation.Int Angiol2008;27:81-5. [PMID: 18277344]

[50] Yanushko VA,Sushkov SA,Nazaruk AM.Benefits of MPFF on primary chronic venous disease-related symptoms and quality of life: the DELTA study.Phlebolymphology2014;21:146-51

[51] Graças C de Souza M, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension.Eur J Vasc Endovasc Surg2018;55:694-702

[52] Kakkos SK.Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.Int Angiol2018;37:143-54

[53] Rodnyansky DV.[Diosmin-containing phlebotropic drugs in varicose eczema].Angiol Sosud Khir2019;25:88-92

[54] Kurginyan HM.Modern view on the therapy of chronic venous insufficiency with micronized purified flavonoid fraction.Cardiovasc Ther Prev2020;19:2592

[55] Ponomarev ÉA,Sotnikov IE.[Use of Detravenol in treatment of chronic venous insufficiency of lower limbs].Angiol Sosud Khir2020;26:95-102

[56] Raffetto JD,Dean SM,Mannello F.Pharmacologic treatment to improve venous leg ulcer healing.J Vasc Surg Venous Lymphat Disord2016;4:371-4

[57] Bush R,Meissner M,Hahn SR.Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).Phlebology2017;32:3-19

[58] Melin MM.RE: A literature review of pharmacological agents to improve venous leg ulcer healing. Letter to the Editor.Wounds2020;32:A10

[59] U.S. Department of Health & Human Services, National Institutes of Health, NCATS. Inxight: Drugs. Vasculera. Available from: https://drugs.ncats.io/drug/Z7R65IFU98. [Last accessed on 12 Mar 2021]

[60] Casili G,Campolo M.Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency.Vascul Pharmacol2021;137:106825

[61] U.S. Department of Health & Human Services, National Institutes of Health, NCATS. Inxight: Drugs. Diosmin. Available from: https://drugs.ncats.io/drug/7QM776WJ5N. [Last accessed on 12 Mar 2021]

[62] Sirtori CR.Aescin: pharmacology, pharmacokinetics and therapeutic profile.Pharmacol Res2001;44:183-93

[63] Stücker M,Hoffmann J.Consensus statement on the symptom-based treatment of chronic venous diseases.J Dtsch Dermatol Ges2016;14:575-83

[64] Peralta GR, Arévalo Gardoqui J, Llamas Macías FJ, Navarro Ceja VH, Mendoza Cisneros SA, Martínez Macías CG. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients.Int Angiol2007;26:378-84

[65] Almeida Cyrino FZG, Balthazar DS, Sicuro FL, Bouskela E. Effects of venotonic drugs on the microcirculation: Comparison between Ruscus extract and micronized diosmine1.Clin Hemorheol Microcirc2018;68:371-82

[66] Kiesewetter H,Kalus U.Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.Arzneimittelforschung2000;50:109-17

[67] Rabe E,Esperester A,Ottillinger B.Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study.Eur J Vasc Endovasc Surg2011;41:540-7

[68] Elleuch N,Bellamine Z,Guerchi M.CVD study investigatorsSulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life.Adv Ther2016;33:1536-49 PMCID:PMC5020111

[69] Chupin AV,Katel’nitskiĭ II.Sulodexide in treatment of chronic venous insufficiency. Results of the All-Russian multicenter programme ACVEDUCT.Angiol Sosud Khir2018;24:47-55. (in Russian)

[70] Carroll BJ,Goldhaber SZ.Sulodexide in venous disease.J Thromb Haemost2019;17:31-8

[71] Gohil KJ,Gajjar AK.Pharmacological Review on Centella asiatica: A Potential Herbal Cure-all.Indian J Pharm Sci2010;72:546-56 PMCID:PMC3116297

[72] Martinez-Zapata MJ,Simancas-Racines D.Phlebotonics for venous insufficiency.Cochrane Database Syst Rev2020;11:CD003229

[73] Karetová D,Bultas J.Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?.Vnitr Lek2020;66:97-103

[74] Lust L,Kohlhaas J,Korff T.Inhibition of cyclooxygenase activity by diclofenac attenuates varicose remodeling of mouse veins.Vessel Plus2021;5:7